{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:52:56Z","timestamp":1790430776695,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Changzhou Science and Technology Program","award":["No. CJ20220222"],"award-info":[{"award-number":["No. CJ20220222"]}]},{"name":"the Young Talent Development Plan of Changzhou Health Commission","award":["No. CZQM2023002"],"award-info":[{"award-number":["No. CZQM2023002"]}]},{"name":"Top Talent of Changzhou \u201cThe 14th Five-year Plan\u201d High-Level Health Talents Training Project","award":["No. 2022260"],"award-info":[{"award-number":["No. 2022260"]}]},{"name":"the Changzhou Key Medical Discipline","award":["No. CZXK202204"],"award-info":[{"award-number":["No. CZXK202204"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-024-03754-0","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T09:02:25Z","timestamp":1726304545000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Single-cell RNA sequencing analysis of peripheral blood mononuclear cells in PD-1-induced renal toxicity in patients with lung cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Shusu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bixia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,14]]},"reference":[{"issue":"4","key":"3754_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","volume":"22","author":"P Darnell Eli","year":"2020","unstructured":"Darnell Eli P, Mooradian Meghan J, Baruch Erez N, et al. Immune-related adverse events (irAEs): diagnosis, management, and clinical Pearls[J]. Curr Oncol Rep. 2020;22(4):39.","journal-title":"Curr Oncol Rep"},{"key":"3754_CR2","doi-asserted-by":"publisher","first-page":"779691","DOI":"10.3389\/fimmu.2022.779691","volume":"13","author":"A Chennamadhavuni Adithya","year":"2022","unstructured":"Chennamadhavuni Adithya A, Laith J, Ning, et al. Risk factors and biomarkers for Immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging Immune Checkpoint Inhibitors[J]. Front Immunol. 2022;13:779691.","journal-title":"Front Immunol"},{"issue":"1","key":"3754_CR3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"J Das Satya","year":"2019","unstructured":"Das Satya J, Douglas B. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors[J]. J Immunother Cancer. 2019;7(1):306.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"3754_CR4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"M Pardoll Drew","year":"2012","unstructured":"Pardoll Drew M. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"3754_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11882-017-0740-z","volume":"17","author":"S Tocheva Anna","year":"2017","unstructured":"Tocheva Anna S, Mor A. Checkpoint inhibitors: applications for Autoimmunity[J]. Curr Allergy Asthma Rep. 2017;17(10):72.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"12","key":"3754_CR6","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/ni.2762","volume":"14","author":"C Okazaki Taku","year":"2013","unstructured":"Okazaki Taku C, Shunsuke I, Yoshiko, et al. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application[J]. Nat Immunol. 2013;14(12):1212\u20138.","journal-title":"Nat Immunol"},{"issue":"12","key":"3754_CR7","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"Y Wang Daniel","year":"2018","unstructured":"Wang Daniel Y, Salem Joe-Elie C, Justine V, et al. Fatal toxic effects Associated with Immune Checkpoint inhibitors: a systematic review and Meta-analysis[J]. JAMA Oncol. 2018;4(12):1721\u20138.","journal-title":"JAMA Oncol"},{"issue":"8","key":"3754_CR8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s11886-021-01530-2","volume":"23","author":"DJ Lee","year":"2021","unstructured":"Lee DJ, Lee Howard J, Farmer Jocelyn R, et al. Mechanisms driving Immune-related adverse events in Cancer patients treated with Immune Checkpoint Inhibitors[J]. Curr Cardiol Rep. 2021;23(8):98.","journal-title":"Curr Cardiol Rep"},{"issue":"4","key":"3754_CR9","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s00432-022-04425-z","volume":"149","author":"S Yamaguchi Atsushi","year":"2022","unstructured":"Yamaguchi Atsushi S, Yoshitaka N, Katsuya, et al. Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1\/PD-L1 inhibitor monotherapy[J]. J Cancer Res Clin Oncol. 2022;149(4):1659\u201366.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"41","key":"3754_CR10","doi-asserted-by":"publisher","first-page":"7190","DOI":"10.3748\/wjg.v27.i41.7190","volume":"27","author":"S Yamada Kentaro","year":"2021","unstructured":"Yamada Kentaro S, Tsunaki N, Masanao, et al. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival[J]. World J Gastroenterol. 2021;27(41):7190\u2013206.","journal-title":"World J Gastroenterol"},{"key":"3754_CR11","doi-asserted-by":"crossref","unstructured":"Naidoo Jarushka C, Tricia R, Lipson Evan J et al. Chronic immune checkpoint inhibitor pneumonitis[J]. J Immunother Cancer, 2020, 8(1).","DOI":"10.1136\/jitc-2020-000840"},{"issue":"1","key":"3754_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/hep.31227","volume":"72","author":"P Thoetchai","year":"2020","unstructured":"Thoetchai P, Jennifer W, Matthew O. Hepatotoxicity from Immune Checkpoint inhibitors: a systematic review and management Recommendation[J]. Hepatology. 2020;72(1):315\u201329.","journal-title":"Hepatology"},{"issue":"2","key":"3754_CR13","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3803\/EnM.2021.1007","volume":"36","author":"K Iwama Shintaro","year":"2021","unstructured":"Iwama Shintaro K, Tomoko AH. Clinical characteristics, management, and potential biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors[J]. Endocrinol Metabolism. 2021;36(2):312\u201321.","journal-title":"Endocrinol Metabolism"},{"issue":"29","key":"3754_CR14","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1200\/JCO.22.00369","volume":"40","author":"NA Rafeh","year":"2022","unstructured":"Rafeh NA, Moey Melissa Y, Natash CT, Xiao-Wei, et al. Major adverse cardiac events with Immune Checkpoint inhibitors: a pooled analysis of trials Sponsored by the National Cancer Institute-Cancer therapy evaluation Program[J]. J Clin Oncol. 2022;40(29):3439\u201352.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3754_CR15","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","volume":"6","author":"P Isik Busra, Alexander Mariam","year":"2021","unstructured":"Isik Busra, Alexander Mariam P, Manohar Sandhya, et al. Biomarkers, clinical features, and rechallenge for Immune checkpoint inhibitor Renal Immune-related adverse Events[J]. Kidney Int Rep. 2021;6(4):1022\u201331.","journal-title":"Kidney Int Rep"},{"issue":"7","key":"3754_CR16","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1158\/1078-0432.CCR-21-1240","volume":"28","author":"W Smithy James","year":"2022","unstructured":"Smithy James W, Faleck David PMA. Facts and hopes in prediction, diagnosis, and treatment of Immune-related adverse Events[J]. Clin Cancer Res. 2022;28(7):1250\u20137.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"3754_CR17","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review [J]. Ann Oncol. 2017;28(10):2377\u201385.","journal-title":"Ann Oncol"},{"issue":"2","key":"3754_CR18","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000455014","volume":"45","author":"K Wanchoo Rimda","year":"2017","unstructured":"Wanchoo Rimda K, Sabine U, Nupur N, et al. Adverse renal effects of Immune Checkpoint inhibitors: a narrative Review[J]. Am J Nephrol. 2017;45(2):160\u20139.","journal-title":"Am J Nephrol"},{"issue":"3","key":"3754_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/CJI.0000000000000338","volume":"44","author":"D Sorah Jonathan","year":"2021","unstructured":"Sorah Jonathan D, Rose Tracy L, Radhakrishna Roshni, et al. Incidence and prediction of Immune Checkpoint inhibitor-related Nephrotoxicity[J]. J Immunother. 2021;44(3):127\u201331.","journal-title":"J Immunother"},{"issue":"12","key":"3754_CR20","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2215\/CJN.00990119","volume":"14","author":"Z Seethapathy Harish","year":"2019","unstructured":"Seethapathy Harish Z, Sophia, Chute Donald F, et al. The incidence, causes, and risk factors of Acute kidney Injury in patients receiving Immune Checkpoint Inhibitors[J]. Clin J Am Soc Nephrol. 2019;14(12):1692\u2013700.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3754_CR21","doi-asserted-by":"crossref","unstructured":"Longhitano Elisa M, Paola LR, Claudia et al. Immune Checkpoint inhibitors and the kidney: a focus on diagnosis and management for Personalised Medicine[J]. Cancers, 2023, 15(6).","DOI":"10.3390\/cancers15061891"},{"issue":"6","key":"3754_CR22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/ajco.13387","volume":"16","author":"H Rongrong","year":"2020","unstructured":"Rongrong H, Xu CM. Renal immune-related adverse events of immune checkpoint inhibitor[J]. Asia-Pac J Clin Oncol. 2020;16(6):305\u201311.","journal-title":"Asia-Pac J Clin Oncol"},{"issue":"2","key":"3754_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.currproblcancer.2016.12.004","volume":"41","author":"M Murakami Naoka","year":"2016","unstructured":"Murakami Naoka M, Shveta, Riella Leonardo V. Renal complications of immune checkpoint blockade[J]. Curr Probl Cancer. 2016;41(2):100\u201310.","journal-title":"Curr Probl Cancer"},{"issue":"6594","key":"3754_CR24","doi-asserted-by":"publisher","first-page":"eabl5197","DOI":"10.1126\/science.abl5197","volume":"376","author":"C Dom\u00ednguez","year":"2022","unstructured":"Dom\u00ednguez C, Cecilia X, Chuan J, Lorna B, et al. Cross-tissue immune cell analysis reveals tissue-specific features in humans[J]. Science. 2022;376(6594):eabl5197.","journal-title":"Science"},{"issue":"3","key":"3754_CR25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/ckj\/sfw024","volume":"9","author":"J Murakami Naoka, Borges Thiago","year":"2016","unstructured":"Murakami Naoka, Borges Thiago J, Yamashita Michifumi, et al. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma[J]. Clin Kidney J. 2016;9(3):411\u20137.","journal-title":"Clin Kidney J"},{"issue":"3","key":"3754_CR26","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","volume":"90","author":"B Cortazar Frank","year":"2016","unstructured":"Cortazar Frank B, Marrone Kristen A, Troxell Megan L, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors[J]. Kidney Int. 2016;90(3):638\u201347.","journal-title":"Kidney Int"},{"issue":"1\u20134","key":"3754_CR27","first-page":"146","volume":"29","author":"T-S Shivtia","year":"2013","unstructured":"Shivtia T-S, Yehudith A, Reuven O. Early cell-cycle gene expression in T-cells after hematopoietic stem cell transplantation[J]. Transpl Immunol. 2013;29(1\u20134):146\u201354.","journal-title":"Transpl Immunol"},{"issue":"10","key":"3754_CR28","doi-asserted-by":"publisher","first-page":"4684","DOI":"10.1111\/jcmm.16407","volume":"25","author":"Z Chen Zhejun","year":"2021","unstructured":"Chen Zhejun Z, Kaiqiong TM, et al. A single-cell survey of the human glomerulonephritis[J]. J Cell Mol Med. 2021;25(10):4684\u201395.","journal-title":"J Cell Mol Med"},{"issue":"44","key":"3754_CR29","doi-asserted-by":"publisher","first-page":"18680","DOI":"10.1073\/pnas.0909307106","volume":"106","author":"MHC International","year":"2009","unstructured":"International MHC, Network AG, John R, Goyette D, Philippe, et al. Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases[J]. PNAS. 2009;106(44):18680\u20135.","journal-title":"PNAS"},{"key":"3754_CR30","doi-asserted-by":"publisher","first-page":"581733","DOI":"10.3389\/fonc.2020.581733","volume":"10","author":"X Zhang Rui","year":"2021","unstructured":"Zhang Rui X, Tao X, Yu, et al. ITM2A as a tumor suppressor and its correlation with PD-L1 in breast Cancer[J]. Front Oncol. 2021;10:581733.","journal-title":"Front Oncol"},{"key":"3754_CR31","doi-asserted-by":"publisher","first-page":"117157","DOI":"10.1016\/j.lfs.2019.117157","volume":"241","author":"G Kirk Sean","year":"2019","unstructured":"Kirk Sean G, Samavati Lobelia L, Yusen. MAP kinase phosphatase-1, a gatekeeper of the acute innate immune response[J]. Life Sci. 2019;241:117157.","journal-title":"Life Sci"},{"issue":"11","key":"3754_CR32","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1161\/CIRCULATIONAHA.112.000826","volume":"127","author":"F Paneni","year":"2013","unstructured":"Paneni F, Osto E, Costantino S, et al. Deletion of the activated protein-1 transcription factor JunD induces oxidative stress and accelerates age-related endothelial dysfunction[J]. Circulation. 2013;127(11):1229\u2013e21.","journal-title":"Circulation"},{"key":"3754_CR33","doi-asserted-by":"publisher","first-page":"574271","DOI":"10.3389\/fimmu.2020.574271","volume":"11","author":"NG Franzin Rossana","year":"2020","unstructured":"Franzin Rossana NG, Stefano S, Federica, et al. The Use of Immune checkpoint inhibitors in Oncology and the occurrence of AKI: where do we Stand[J]. Front Immunol. 2020;11:574271.","journal-title":"Front Immunol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03754-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-024-03754-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03754-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T01:02:44Z","timestamp":1726448564000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-024-03754-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,14]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3754"],"URL":"https:\/\/doi.org\/10.1186\/s12882-024-03754-0","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,14]]},"assertion":[{"value":"14 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of the Third Affiliated Hospital of Soochow University (Grant No. 2022[039]). The study protocol adhered to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All patients signed an informed consent before enrolment in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"307"}}